oborI dual antiplatelet therapy as aPPropriate duratiON (NIPPON) - NoborI dual antiplatelet therapy as aPPropriate duratiON (NIPPON)

PO Associations for Establishment of Evidence in Interventions0 sites4,598 target enrollmentDecember 1, 2011

ConditionsCoronary Artery Disease

Overview

Phase: 未知
Intervention: Not specified
Conditions: Coronary Artery Disease
Sponsor: PO Associations for Establishment of Evidence in Interventions
Enrollment: 4598
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

December 1, 2011

End Date

June 30, 2015

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

PO Associations for Establishment of Evidence in Interventions

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\. Patient with cardiogenic shock. 2\. Patient who needs continuous treatment of thienopyridine. 3\. Patient with a history of stent thrombosis. 4\. Patient who is confirmed to have an allergy or hypersensitivity to sirolimus or substance with a structure similar to biolims\-A9 (ex., tacrolimus, everolimus). 5\. Patient who is confirmed to have an allergy or not to have a tolerability to antiplatelet agents, anticoagulants or a contrast medium. 6\. Patient who is confirmed to have an allergy or hypersensitivity to materials of Nobori biolims A\-9 eluting stent. 7\. Patient with a hemorrhagic predisposition or a history of coagulation abnormality. 8\. Patient whose left ventricular ejection fraction (LVEF) is \< 30%. 9\. Patient under pregnancy (present, suspected or planned). 10\. Patient who has a life expectancy of less than 12 months. 11\. Patient who has an active bleeding. 12\. Patient who is scheduled to undergo treatment requiring discontinuation of an antiplatelet agent. 13\. Patient with a verified history of cerebral apoplexy or intracranial bleeding within 6 months before stenting. 14\. Patient who is scheduled to undergo stent treatment in other lesions after the 30th day of the registration. 15\. Patient who is received the follow\-up observation. 16\. Patient who has unprotected LMT lesion (50%\>%DS). 17\. Patients disqualified from participation by the investigator/sub\-investigator. 18\. Patient who underwent stent treatment with DES 6 months prior to the conduct of index PCI. 19\. Lesions located within the saphenous venin graft (SVG). 20\. Lesions with an anatomical structure of the coronary artery that is not eligible for treatment by the deployment of Nobori biolimus\-A9 stent. 21\. Lesions of in\-stent restenosis in previously deployed DES.